Comparative Pharmacology
Head-to-head clinical analysis: DILACOR XR versus VERILOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILACOR XR versus VERILOID.
DILACOR XR vs VERILOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.
VERILOID is a synthetic alkaloid that acts as a ganglionic blocker, inhibiting nicotinic acetylcholine receptors at autonomic ganglia, leading to reduced sympathetic and parasympathetic outflow. This results in vasodilation and decreased peripheral vascular resistance, lowering blood pressure.
180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.
Intravenous: 0.1-0.5 mg/kg bolus, followed by 0.5-2 mcg/kg/min continuous infusion. Oral: 20-80 mg every 6-8 hours.
None Documented
None Documented
Terminal half-life: 6-12 hours (prolonged in elderly, hepatic impairment, or with CYP3A4 inhibitors)
Terminal elimination half-life is 3-5 hours, clinically relevant for dose scheduling to maintain steady-state levels.
Renal (70% as metabolites, 3-4% as unchanged drug); biliary/fecal (25-30%)
Renal excretion accounts for approximately 60% as unchanged drug; hepatic metabolism contributes 30% with biliary-fecal elimination of metabolites, totaling ~10% fecal.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker